Anschutz Cancer Pavilion
1665 North Aurora Court
Aurora, CO 80045
Knowledge gaps around the preferences of older patients with advanced bladder cancer prompted Elizabeth Kessler, MD, and colleagues to better understanding this patient population.
Peter Forsberg, MD, reviews options for treatment sequencing and initiating treatment for relapsed/refractory multiple myeloma.
A new way of assessing cancer lesions’ response to treatment could pave the way for developing new cancer therapeutics.
PARP inhibitors can play a significant role in the first-line setting for patients with advanced ovarian cancer.